Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9091
pubmed:dateCreated
1998-1-6
pubmed:commentsCorrections
pubmed:keyword
http://linkedlifedata.com/resource/pubmed/keyword/Africa, http://linkedlifedata.com/resource/pubmed/keyword/Americas, http://linkedlifedata.com/resource/pubmed/keyword/Asia, http://linkedlifedata.com/resource/pubmed/keyword/Critique, http://linkedlifedata.com/resource/pubmed/keyword/Developing Countries, http://linkedlifedata.com/resource/pubmed/keyword/Drugs--therapeutic use, http://linkedlifedata.com/resource/pubmed/keyword/Economic Factors, http://linkedlifedata.com/resource/pubmed/keyword/Financial Activities, http://linkedlifedata.com/resource/pubmed/keyword/Foreign Aid, http://linkedlifedata.com/resource/pubmed/keyword/Organization And Administration, http://linkedlifedata.com/resource/pubmed/keyword/Program Development, http://linkedlifedata.com/resource/pubmed/keyword/Programs, http://linkedlifedata.com/resource/pubmed/keyword/South America, http://linkedlifedata.com/resource/pubmed/keyword/Southeastern Asia, http://linkedlifedata.com/resource/pubmed/keyword/Treatment
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0140-6736
pubmed:author
pubmed:issnType
Print
pubmed:day
29
pubmed:volume
350
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1624-5
pubmed:dateRevised
2010-11-18
pubmed:otherAbstract
PIP: Glaxo Wellcome announced in November 1996 its intent to donate up to 1 million treatment courses per year of its new antimalarial drug, Malarone, to countries in Africa, Southeast Asia, and South America, where malaria is endemic. Because the effectiveness of the small number of available antimalarial drugs is threatened by the emergence of drug resistance, the advantages of introduction of this new drug to a given area should be given careful consideration. Chloroquine, for example, is nearing the end of its effectiveness as a first-line drug for the treatment of uncomplicated falciparum malaria in many areas of East and Central Africa. The lifespan of its replacement, sulfadoxine-pyrimethamine, is likely to be even shorter given its long half-life and the ease with which resistance-conferring mutations occur. In Southeast Asia and the Amazon basin of South America, where multidrug-resistant Plasmodium falciparum malaria is a serious problem, the advantages of Malarone introduction clearly outweigh any disadvantages. In sub-Saharan Africa, the premature distribution and increasing use of artemisinins may jeopardize their long-term effectiveness, however. Another factor complicating decisions to introduce Malarone is its required 3-day course of treatment, necessitating hospitalization if compliance is to be ensured. The donation project gives patients in developing countries access to an expensive drug that would otherwise be unavailable. Time must be taken, however, to fully debate the project's pros and cons, resolve inherent logistic problems, and establish guidelines for Malarone use in sub-Saharan Africa.
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Malarone-donation programme in Africa.
pubmed:affiliation
Malaria Epidemiology Section, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA.
pubmed:publicationType
Journal Article